ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
CLINICAL & PIPELINEClinical Trial CompletionNotable

Cairo University Completes Clinical Study NCT05579535 on Gait Intervention for Pediatric Spastic Diplegia

RM
Rohan MehtaView Profile →
Senior Supply Chain Intelligence Analyst
EXECUTIVE SUMMARY

Cairo University has completed clinical study NCT05579535, investigating the effect of ankle weights on hip excursion in children with spastic diplegia. This interventional study, led by Nahla Mohamed Ibrahim, provides critical data for non-pharmacological approaches in pediatric neurological rehabilitation. Decision-makers should monitor results for potential impacts on physical therapy protocols and rehabilitation product development.

Clinical Study Completion: Cairo University's Gait Intervention for Spastic Diplegia

Cairo University, an academic institution based in Egypt, has officially completed its interventional clinical study, NCT05579535, titled 'Effect of Weight on Hip Excursion During Gait in Children With Diplegia.' The study, which commenced on August 3, 2022, and reached its primary completion date on October 3, 2022, with overall completion by October 7, 2022, focused on a critical aspect of pediatric neurological rehabilitation: managing gait abnormalities in children diagnosed with spastic diplegic cerebral palsy. The principal investigator, Nahla Mohamed Ibrahim, a lecturer at the pediatric department, faculty of physical therapy at Cairo University, led this research effort. The trial was designed as a randomized, parallel-group study with single masking (participants were masked) to investigate the efficacy of using weight around the ankle during gait training. This approach aimed to specifically assess its impact on hip excursion, a key biomechanical parameter in the gait cycle. For procurement directors and business development executives, this completion signals a potential shift or reinforcement in non-pharmacological treatment modalities, which could influence demand for specific rehabilitation equipment or training programs in the future. The study’s focus on a specific, measurable outcome like hip excursion provides a clear metric for evaluating intervention effectiveness, which is valuable for evidence-based practice.

Therapeutic Implications for Pediatric Neurological Conditions

The completed study NCT05579535 directly addresses the indication of 'Gait, Spastic,' a common challenge in pediatric neurology. Children with diplegia often exhibit considerably larger hip and knee excursion during gait compared to typically developing children, necessitating targeted interventions. This trial explored a practical, non-invasive physical therapy technique: incorporating ankle weights into gait training. Fifty children, aged 7 to 10 years, diagnosed with spastic diplegia and classified as level II on the Gross Motor Function Classification System (GMFCS), were enrolled. They were randomized into two groups: one receiving classical gait training (Group A) and another receiving gait training with ankle weights (Group B). Both groups underwent one-hour sessions, three times per week, for three consecutive months. For regulatory affairs heads, the non-pharmacological nature of this intervention means it falls outside typical drug or device regulatory pathways, as confirmed by its `isFdaRegulatedDrug: false` and `isFdaRegulatedDevice: false` status. However, the outcomes, once published, could inform clinical practice guidelines and potentially influence the design and adoption of rehabilitation protocols globally. Supply chain VPs should note that successful results could drive demand for specific types of weighted rehabilitation equipment, impacting sourcing strategies for physical therapy clinics and hospitals.

Research Landscape and Future Directions in Physical Rehabilitation

The completion of Cairo University's study NCT05579535 contributes to the growing body of evidence in physical rehabilitation, particularly for neurological conditions. While the study results are not yet publicly available (`hasResults: false`), its completion marks a significant milestone in understanding adjunctive therapies for spastic gait. The methodology, involving two-dimensional (2D) gait analysis for objective measurement of hip excursion, underscores a commitment to quantitative assessment in physical therapy. This aligns with a broader industry trend towards data-driven clinical outcomes. For business development executives, this highlights an active area of academic research that, while not directly a drug approval, could generate insights for new medical device innovations or service offerings in pediatric rehabilitation. The focus on a specific, measurable biomechanical outcome provides a clear target for future research or product development. The broader clinical research landscape, as evidenced by recent parallel events such as AbbVie's FDA approval for RINVOQ LQ or Dr. Falk Pharma's Phase III trial completion for Budesonide, demonstrates continuous innovation across diverse therapeutic areas, including both pharmacological and non-pharmacological interventions. This Cairo University study, though distinct in its focus, reinforces the global commitment to advancing patient care through rigorous clinical investigation.

Operational Insights for Clinical Trial Management and Data Transparency

From an operational standpoint, the Cairo University study NCT05579535 offers valuable insights for clinical trial management and data transparency. The trial was sponsored by Cairo University, with Nahla Mohamed Ibrahim serving as the principal investigator, highlighting an academic-led research model. The study was conducted in Giza, Egypt, indicating regional capabilities in clinical research. Crucially, the trial maintained robust oversight, confirmed by `oversightHasDmc: true`, signifying the presence of a Data Monitoring Committee to ensure patient safety and data integrity. For regulatory affairs heads and procurement directors involved in clinical operations, the explicit statement regarding data sharing is noteworthy: the study protocol and other information types will be available upon contacting the corresponding author after online publication. This commitment to `ipdSharing: YES` and the provision of `infoTypes: [STUDY_PROTOCOL]` sets a precedent for transparency in academic research, enabling broader scientific scrutiny and potential meta-analyses. Understanding these operational details is vital for organizations considering collaborations in emerging research hubs or for those benchmarking best practices in clinical trial governance and data dissemination, particularly for studies that are not subject to stringent FDA or EMA drug/device regulations but still adhere to ethical and scientific standards.

Strategic Considerations for Rehabilitation Product Development

While this clinical study did not involve a pharmaceutical product or a regulated medical device, its findings, once published, could significantly influence strategic planning for companies in the rehabilitation and medical equipment sectors. The intervention — using weight around the ankle during gait training — directly points to a potential market for specialized weighted devices or integrated rehabilitation systems. Business development executives should consider how positive outcomes from this study could stimulate demand for ergonomically designed ankle weights, smart wearable devices that monitor gait parameters, or comprehensive physical therapy programs incorporating such techniques. The focus on children aged 7-10 years with spastic diplegia also defines a specific patient demographic, allowing for targeted product development and marketing strategies. Furthermore, the use of 2D gait analysis as a primary outcome measure suggests an opportunity for companies developing diagnostic and monitoring tools for gait abnormalities. Procurement directors in healthcare systems should anticipate potential future requirements for such non-pharmacological aids, necessitating proactive engagement with suppliers of rehabilitation equipment to ensure access to evidence-based tools. This study underscores the importance of monitoring academic research for signals that can drive innovation and market shifts in adjunctive therapies.

ChemLifeIntel analysis · Rohan Mehta. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 10,000+ pharmaceutical and chemical companies across the global value chain.

Covering 10,000+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

CLINICAL & PIPELINE
1 min ago

AbbVie Secures FDA Approval for RINVOQ LQ (Upadacitinib) Oral Solution: Strategic Expansion with Orphan Designation

AbbVie has secured FDA approval for RINVOQ LQ (Upadacitinib) 1MG/ML oral solution, a new dosage form for its existing Janus Kinase Inhibitor. This Type 3 submission, with Orphan Drug designation, was approved on April 26, 2024, expanding patient access and market opportunities for Upadacitinib, particularly for those needing liquid formulations.

CLINICAL & PIPELINE
22h ago

Duboce Biopharmaceuticals Initiates Phase 1a/1b Clinical Trial for Novel Biologic DBC-664 in Advanced Solid Tumors

Duboce Biopharmaceuticals, Inc. has commenced a Phase 1a/1b clinical trial (NCT07705035) for its novel biologic, DBC-664, targeting advanced solid tumors. This first-in-human study, recruiting 210 patients, will assess safety, pharmacokinetics, and preliminary anti-tumor activity. This move signals Duboce's strategic entry into the competitive oncology market, impacting future development and partnership opportunities for stakeholders.

CLINICAL & PIPELINE
22h ago

Memorial Sloan Kettering Completes Phase 2 BMT Trial for Genetic Blood Disorders

Memorial Sloan Kettering Cancer Center has completed a Phase 2 clinical trial (NCT00578435) on allogeneic bone marrow transplantation for severe genetic erythropoiesis disorders. This comprehensive study, concluded in 2008, evaluated BMT's role in treating sickle cell anemia, thalassemia, and Diamond Blackfan anemia, utilizing specific conditioning and prophylaxis regimens. Its findings inform future therapeutic development and supply chain strategies for critical BMT pharmaceuticals.

CLINICAL & PIPELINE
4d ago

Infinity Pharmaceuticals' IPI-504 Phase 2 Trial for ALK-Positive NSCLC Terminated Due to Slow Accrual

Infinity Pharmaceuticals, Inc. faces a strategic setback with the termination of its Phase 2 clinical trial (NCT01228435) for IPI-504, an Hsp90 inhibitor, in ALK-positive NSCLC patients. The trial, led by Massachusetts General Hospital, ceased due to slow accrual, having enrolled only three participants. This event impacts future R&D investments and competitive positioning in targeted oncology therapies.

CLINICAL & PIPELINE
4d ago

Mayo Clinic Advances Diffuse Midline Glioma Treatment with Phase 2 SPORT-DMG Radiation Trial

Mayo Clinic has initiated a Phase 2 clinical trial (NCT05077735) for hypofractionated radiation therapy in Diffuse Midline Glioma, H3 K27M-Mutant. This SPORT-DMG trial aims to assess a shorter, 2-week radiation course against the standard 6-week regimen, targeting improved 10-month overall survival and patient quality of life. This development signals potential shifts in oncology treatment protocols for this aggressive brain cancer.

CLINICAL & PIPELINE
4d ago

Aurion Biotech Completes Phase 1 Clinical Trial for HCEC-1 in Corneal Edema

Aurion Biotech has completed its Phase 1 clinical trial (NCT05309135) for HCEC-1, a novel human corneal endothelial cell therapy combined with Rho kinase inhibitor Y-27632, targeting corneal edema secondary to endothelial dysfunction. This milestone de-risks early-stage development, paving the way for potential advancement into later clinical phases and signaling a significant step in regenerative ophthalmic treatments.

CLINICAL & PIPELINE
5d ago

FDA Advisory Panel Recommends Expanded Compounding Access for Peptides BPC-157, KPV, TB-500, and MOTS-c

The FDA's advisory panel recommended allowing compounding pharmacies to manufacture BPC-157, KPV, TB-500, and MOTS-c. This non-binding vote, influenced by peptide industry ties, signals potential for significantly expanded market access for these unapproved substances. Decision-makers must prepare for increased demand for these APIs and evolving regulatory oversight in the US market.

CLINICAL & PIPELINE
5d ago

Eli Lilly's Retatrutide Filing Signals Intensified Obesity Market Competition and Supply Chain Pressures

Eli Lilly is set to file for FDA approval of its triple-agonist retatrutide in Q1 2027, intensifying competition in the rapidly expanding obesity market. This move, following strong Phase 3 data, highlights significant supply chain and manufacturing demands. Procurement and regulatory teams must monitor Lilly's capacity and market shifts closely.

CLINICAL & PIPELINE
6d ago

GSK's Jideytro FDA Approval Bolsters Oncology Portfolio After $10.6B Nuvalent Acquisition

GSK secured FDA approval for Jideytro (zidesamtinib) for ROS1-positive metastatic NSCLC, a key return on its $10.6 billion Nuvalent acquisition. This approval accelerates GSK's oncology expansion, positioning Jideytro as a next-generation therapy in a competitive but underserved market, with significant implications for procurement and market access strategies.

CLINICAL & PIPELINE
6d ago

Summit Therapeutics Bolsters Ivonescimab's FDA Case with Updated Phase 3 Survival Data

Summit Therapeutics has strategically released updated overall survival data from its Phase 3 HARMONi trial for ivonescimab, a PD-1xVEGF bispecific antibody. This move aims to bolster the drug's profile ahead of a critical FDA decision, signaling a proactive regulatory approach. Decision-makers should monitor this development closely for its implications on future oncology treatment landscapes and potential supply chain shifts in the United States.

CLINICAL & PIPELINE
6d ago

University of Massachusetts Completes Pivotal MST-EA Trial for Antisocial Behavior in Emerging Adults

The University of Massachusetts, Worcester, has completed a pivotal clinical trial (NCT02922335) for Multisystemic Therapy-Emerging Adults (MST-EA). This behavioral intervention targets serious antisocial behavior in emerging adults with mental illness, addressing a critical unmet public health need. The completion signals a potential shift in evidence-based mental health service delivery for high-risk populations, impacting future procurement and policy.

CLINICAL & PIPELINE
6d ago

Sun Yat-sen University Advances Anlotinib in Phase 4 Head and Neck Cancer Trial (NCT04507035)

Sun Yat-sen University is conducting a Phase 4 clinical trial (NCT04507035) evaluating Anlotinib hydrochloride capsules combined with chemoradiotherapy for locally advanced head and neck cancer. This study, led by Principal Investigator Zhen-Wei Peng, targets improved survival and tumor regression in refractory cases. For procurement and business development, this highlights emerging treatment paradigms and potential market shifts in oncology.

ENTITY HUBS

Entities in this Brief

China Pharmaceutical University
company hub
Open company hub